MedWatch

Novo Nordisk expands research collaboration to develop hemophilia drug

Collaborations between Novo Nordisk and US-based biotech firm 2Seventy Bio, spun off from Bluebird Bio, have expanded to include the development of a treatment for bleeding disorder hemophilia A.

Photo: Stine Tidsvilde

Under the banner of a joint research and development, Novo Nordisk and US-based biotech firm 2Seventy Bio will develop a drug candidate for genetic bleeding disorder hemophilia A, reports a press release from 2Seventy Bio.

The partnership builds upon an existing research collaboration between the two companies. Under the terms of the new deal, 2Seventy Bio receives an upfront payment of USD 5m, and the company is eligible for milestone payments of up to USD 35m as well as potential royalties from sales of the drug.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs